"Designing Growth Strategies is in our DNA"

Adalimumab Biosimilar Market Size, Share And Global Trend By Product (Exemptia, Adalirel, Cipleumab, Others), By Distribution channel (Hospitals pharmacies, Retail pharmacies, Others), And Geography Forecast Till 2030

Region : Global | Report ID: FBI100594 | Status : Ongoing



A biosimilar is a type of biologic equivalent to that of pre-approved biologics. Adalimumab was the first fully human monoclonal antibody approved by the U.S. Food and Drug Administration in December 2002. Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and many other diseases. In September 2017, AbbVie Inc. lost patent of Humira, which led other manufacturers to introduce biosimilars of adalimumab in the market. Exemptia is the world’s first biosimilar of adalimumab, launched by Cadila Healthcare in December 2014.

The global adalimumab biosimilars market is expected to grow at a rapid pace during the forecast period, owing to the increasing incidence of arthritis among the global population and increase in the number of skin disorders leading to rise in demand for adalimumab. Additionally, the introduction of new biosimilars will lead to the decline in prices of the drugs in the global market, subsequently leading to high demand in the market. This is projected to fuel the growth of the global adalimumab biosimilars market during the forecast period.

To gain extensive insights into the market, Request for Customization

The factor that is expected to inhibit the growth of the market is the high sensitivity towards temperature, lack of efficacy and safety, high manufacturing cost compared to generic drugs.

Key Players Covered

Some of the major companies that are present in the global adalimumab biosimilar market are Alfred E. Tiefenbacher, Amgen Inc., Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Ltd, Zydus Cadila, Torrent Pharmaceuticals Ltd., Reliance Life Sciences., Emcure Pharmaceuticals Ltd, Cipla Inc., Hetero. and others.  




By Product

·         Exemptia

·         Adalirel

·         Cipleumab

·         Others

By Distribution channel

·         Hospitals pharmacies

·         Retail pharmacies

·         Others

By Geography

·      North America (USA and Canada)

·      Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

·      Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

·      Latin America (Brazil, Mexico and Rest of Latin America)

·      Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)


At present, the Exemptia is anticipated to account for the largest market share being the first biosimilar of adalimumab to be approved.

Key Insights

Pipeline analysis

Introduction of new products/approvals (by major players)

Key strategies by market players

Prevalence of arthritis and skin diseases (key regions/ countries).

Regional Analysis

The global adalimumab biosimilar market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America is anticipated to account for the largest share of the global adalimumab biosimilars market in 2018, owing to the increasing prevalence of rheumatoid arthritis combined with the rise in the geriatric population. Europe is expected to grow at a faster rate owing to a rise in the approvals of the new biosimilars, rise in aging population, high investment in the research and manufacturing of the new adalimumab biosimilars.  As of 2018, five new adalimumab biosimilars have been approved in Europe, including AMGEVITA. These new biosimilars are expected to drive the growth of the global adalimumab biosimilars market in the forecast period. The increased focus to develop generic and biosimilar products in the emerging nations of Asia Pacific is estimated to fuel in the global adalimumab biosimilars market in these regions.

Key Industry Developments

  • In October 2018, Samsung Bioepis launched IMRALDITM a biosimilar to adalimumab with joint venture between Samsung BioLogics and Biogen.

  • In November 2018, Food and Drug Administration approved the Hyrimoz adalimumab biosimilar developed by Novartis AG.

  • In October 2018, Amgen Inc., launched AMGEVITA a biosimilar of adalimumab.

  • In August, 2017, Boehringer Ingelheim International GmbH received approval for the Cyltezo, a biosimilar of adalimumab. 

  • Ongoing
  • 2022
  • 2019-2021


  • $4850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

Siemens Healthineers

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.